<DOC>
	<DOCNO>NCT00751595</DOCNO>
	<brief_summary>The study randomize , open label , phase II clinical trial direct evaluate immunogenicity ( primary end-point ) safety ( secondary end-point ) , recombinant HIV-1 Tat vaccine HIV-1 infect adult subject , anti-Tat antibody negative , HAART-treated chronic suppress HIV-1 infection , CD4+ T cell count &gt; = 200 cells/microliter , level plasma viremia &lt; 50 copies/ml last 6 month prior screen without history virologic rebound . The immunogenicity 3 5 immunization two different vaccine dos ( 7.5 30 microgram ) Tat vaccine evaluate .</brief_summary>
	<brief_title>Immunogenicity Safety Trial HIV-1 Tat Vaccine</brief_title>
	<detailed_description>This phase II clinical trial direct evaluate immunogenicity safety HIV-1 Tat protein-based vaccine . Anti-Tat antibody negative , HIV-1 positive subject treat successfully HAART screen recruit 48-weeks study , include period 16 8 week treatment phase period 32 40 week follow-up phase , arm A Arm B , respectively . One hundred sixty-eight subject randomize 1:1:1:1 one 2 arm ( Arm A Arm B ) arm divide follow group : Arm A - Group I : 5 immunization Tat ( 7.5 microg ) week 0 , 4 , 8 , 12 , 16 ; Arm A - Group II : 5 immunization Tat ( 30 microg ) week 0 , 4 , 8 , 12 , 16 ; Arm B - Group I : 3 immunization Tat ( 7.5 microg ) week 0 , 4 , 8 ; Arm B - Group II : 3 immunization Tat ( 30 microg ) week 0 , 4 , 8 . Four vaccination regimen test intradermal administration Tat vaccine two different dos ( 7.5 microg 30 microg ) 5 3 immunization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 1855 year AntiTat antibody negative subject HIV1 infect subject successful HAART treatment HIV plasma viremia &lt; 50 copies/ml last 6 month prior screen Subjects preHAART CD4 nadir ; CD4+ T cell count ≥ 200 cells/μl enrolment ; Availability plan study duration Negative pregnancy test woman childbearing potential ( perform screen phase immunization ) use acceptable mean contraception ( condom , hormonal mechanical method ) one month prior immunization duration study Signed informed consent Concomitant AIDSrelated opportunistic disease ; Concomitant neoplastic disease ; History malignant neoplastic disease [ NOTE : Subjects history non malignant neoplastic disease completely resolve accord fulfillment specific recovery criterion , agreement current guideline medical oncology eligible ] ; History encephalopathy , neuropathy unstable CNS pathology , immunodeficiency , autoimmune disease , angina cardiac arrhythmia , clinically significant medical problem ; Any evidence , judge investigator , unstable cardiovascular disease ( e.g . unstable hypertensive disease need modification introduction antihypertensive treatment ) ; Chest radiography show evidence active acute cardiac pulmonary disease within 6 month prior study screen visit ; History anaphylaxis serious adverse reaction vaccine well serum IgE level exceed 1000 U.I./ml ; History serious allergic reaction substance , require hospitalization emergent medical care ( e.g . StevenJohnson syndrome , bronchospasm , hypotension ) ; Active tuberculosis document PPD skin test within one year [ NOTE : PPD skin test positive , chest xray do finding consistent active pulmonary tuberculosis indication exist prophylaxis treatment , subject eligible participation trial ] ; Medical psychiatric condition preclude subject compliance protocol . Specifically , person psychotic disorder , major affective disorder , suicidal ideation exclude ; Current use psychotropic drug prescribe major psychotic disorder ; Concomitant participation experimental study ; Current prior therapy immunomodulators immunosuppressive drug anticoagulant drug within 30 day prior study medication administration ; Live attenuate vaccine within 60 day study inclusion [ NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal , hepatitis A B ) exclusionary , give least 4 week away HIV immunization ] ; Receipt blood product immunoglobulin past year ; Previous participation HIV1 vaccine trial ( subject despite participation placebo HIV1 vaccine trial never effectively administer HIV1 vaccine eligible ) ; Drug and/or alcohol abuse ; Use last 6 month concomitant use anti CCR5 inhibitor and/or integrase inhibitor and/or fusion inhibitor ; Pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tat protein</keyword>
	<keyword>Therapeutic vaccine</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>